Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Selecta Biosciences Inc is a biotechnology business based in the US. Selecta Biosciences shares (SELB) are listed on the NASDAQ and all prices are listed in US Dollars. Selecta Biosciences employs 58 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $1.33 |
|---|---|
| 52-week range | $0.65 - $4.70 |
| 50-day moving average | $0.95 |
| 200-day moving average | $2.36 |
| Wall St. target price | $7.29 |
| PE ratio | 16.375 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.08 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.33 from 2022-07-01
| 1 week (2022-06-28) | 2.31% |
|---|---|
| 1 month (2022-06-03) | 50.71% |
| 3 months (2022-04-01) | N/A |
| 6 months (2022-01-01) | N/A |
| 1 year (2021-07-02) | -68.78% |
|---|---|
| 2 years (2020-07-02) | -51.46% |
| 3 years (2019-07-05) | 1.74 |
| 5 years (2017-07-05) | 19.58 |
Valuing Selecta Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Selecta Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Selecta Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Selecta Biosciences shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Selecta Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14 million.
The EBITDA is a measure of a Selecta Biosciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $108 million |
|---|---|
| Operating margin TTM | 12.34% |
| Gross profit TTM | $16.3 million |
| Return on assets TTM | 5.17% |
| Return on equity TTM | 153% |
| Profit margin | 25.63% |
| Book value | $0.45 |
| Market capitalisation | $198.9 million |
TTM: trailing 12 months
We're not expecting Selecta Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Selecta Biosciences's shares have ranged in value from as little as $0.647 up to $4.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Selecta Biosciences's is 1.3385. This would suggest that Selecta Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Selecta Biosciences, Inc. , a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.